Fig. 5

CARTp dampens LPS-triggered inflammation. A Representative photomicrographs showing c-Fos immunoreactivity, and summary c-Fos positive cell counts, in the caudal DMN and NTS of mice treated with either scrambled CARTp or CARTp followed by LPS administration. Uninjected controls are shown for comparison. B Representative images showing CARTp immunoreactivity in the spleen in vehicle- and LPS-treated mice. LPS causes a decrease in CARTp immunoreactivity, presumably due to its release from vagal efferents. C Summary data showing the plasma levels of IL-1ß in mice 3 h after injection with LPS given following intrasplenic infusion of either 9 µg/kg control IgG or 9 µg/kg anti-CART antibodies. Uninjected mice were used as baseline controls. D Summary data showing the levels of IL-1ß in the plasma of mice 3 h after injection with LPS following intrasplenic infusion of either 3.8 µg/kg scrambled CARTp or 3.8 µg/kg synthetic CARTp. Uninjected mice were used as baseline controls. Data are presented as the mean ± SEM. *, p < 0.05